LIPID APP was conceived as a device aimed at facilitating the doctor in defining the patient's cardiovascular risk level and setting the most appropriate therapeutic choice.
By entering information relating to the patient's various cardiovascular risk factors, the level of risk of fatal events in the next 10 years is automatically estimated, derived from the SCORE system (Systematic Coronary Risk Evaluation).
LIPID APP also provides information on the LDL cholesterol target recommended by the guidelines in relation to the level of risk and the distance of the patient's LDL cholesterol level from the target recommended by the guidelines.
Finally, LIPID APP indicates the therapeutic options with the greatest a priori probability of obtaining a reduction in LDL cholesterol levels sufficient to reach the recommended target.
LIPID APP does not in any way replace the judgment of the doctor who is responsible for evaluating the adequacy of what is highlighted by the app in relation to the clinical context.
The information presented in the LIPID APP was derived from the ESC / EAS guidelines for the management of dyslipidemias of 2019 and 2016.
By entering information relating to the patient's various cardiovascular risk factors, the level of risk of fatal events in the next 10 years is automatically estimated, derived from the SCORE system (Systematic Coronary Risk Evaluation).
LIPID APP also provides information on the LDL cholesterol target recommended by the guidelines in relation to the level of risk and the distance of the patient's LDL cholesterol level from the target recommended by the guidelines.
Finally, LIPID APP indicates the therapeutic options with the greatest a priori probability of obtaining a reduction in LDL cholesterol levels sufficient to reach the recommended target.
LIPID APP does not in any way replace the judgment of the doctor who is responsible for evaluating the adequacy of what is highlighted by the app in relation to the clinical context.
The information presented in the LIPID APP was derived from the ESC / EAS guidelines for the management of dyslipidemias of 2019 and 2016.
Show More
